Engineering the microcirculation

Tissue Engineering - Part B: Reviews

Volumn 14, Issue 1, 2008, Pages 87-103

  Lokmic, Zerina ^a,b   Mitchell, Geraldine M ^a  

^a Bernard O'Brien Institute of Microsurgery   (Australia)

^b Institute for Physiological Chemistry and Pathobiochemistry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; GROWTH (MATERIALS); MICROCIRCULATION; MODELS; PEPTIDES; SCAFFOLDS; TISSUE;

BLOOD SUPPLIES; ENGINEERED TISSUES; ENGINEERING MODELS; GROWTH FACTOR DELIVERIES; GROWTH FACTORS; IN VITRO; IN-VIVO; MICROENVIRONMENT; NETWORK FORMATIONS; SCAFFOLD PROPERTIES; VASCULAR REMODELING; VASCULARIZATION;

TISSUE ENGINEERING;

COLLAGEN TYPE 1; FIBRIN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL; CAPILLARY ENDOTHELIUM; CELL ADHESION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROCIRCULATION; MICROVASCULATURE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE ENGINEERING; VASCULARIZATION; ANIMAL; AUDIOVISUAL EQUIPMENT; BIOARTIFICIAL ORGAN; BIOLOGICAL MODEL; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; HISTOLOGY; INSTRUMENTATION; METHODOLOGY; MOUSE; PATHOLOGY; RAT; THEORETICAL MODEL; VASCULAR ENDOTHELIUM;

ANIMALS; BIOARTIFICIAL ORGANS; BLOOD VESSELS; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; MICE; MICROCIRCULATION; MODELS, ANATOMIC; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; TISSUE ENGINEERING;

EID: 44949173153     PISSN: 19373368     EISSN: None     Source Type: Journal    
DOI: 10.1089/teb.2007.0299     Document Type: Review

References (173)

1. Langer R, Vacanti JP. Tissue engineering. Science 260, 920, 1993.
2. Godbey WT, Atala A. In vitro systems for tissue engineering. Ann N Y Acad Sci 961, 10, 2002.
3. Tabata Y. Recent progress in tissue engineering. Drug Discov Today 6, 483, 2001.
4. Tanaka Y, Sung KC, Tsutsumi A, Ohba S, Ueda K, Morrison WA. Tissue engineering skin flaps: which vascular carrier, arteriovenous shunt loop or arteriovenous bundle, has more potential for angiogenesis and tissue generation? Plast Reconstr Surg 112, 1636, 2003.
5. Tanaka Y, Tsutsumi A, Crowe DM, Tajima S, Morrison WA. Generation of an autologous tissue (matrix) flap by combining an arteriovenous shunt loop with artificial skin in rats: preliminary report. Br J Plas Surg 53, 51, 2000.
6. Cassell OC, Hofer SO, Morrison WA, Knight KR. Vascularization of tissue-engineered grafts: the regulation of angiogenesis in reconstructive surgery and in disease states. Br J Plast Surg 55, 603, 2002.
7. Frerich B, Lindemann N, Kurtz-Hoffmann J, Oertel K. In vitro model of a vascular stroma for the engineering of vascularized tissues. Int J Oral Maxillofac Surg 30, 414, 2001.
8. Krogh A. The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol 52, 409, 1919.
9. Beacham WS, Konishi A, Hunt CC. Observations of the microcirculatory bed in rat mesocecum using differential interference contrast microscopy in vivo and electron microscopy. Am J Anat 146, 385, 1976.
10. Rhodin JA. The ultrastructure of mammalian arterioles and precapillary sphincters. J Ultrastr Res 18, 181, 1967.
11. Stingl J. Fine structure of precapillary arterioles of skeletal muscle in the rat. Acta Anat 96, 196, 1976.
12. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 17, 1193, 1997.
13. Nguyen LL, D'Amore PA. Cellular interactions in vascular growth and differentiation. Int Rev Cytol 204, 1, 2001.
14. Simionescu N, Simionescu M. The cardiovascular system. In: Weiss L., ed. Cell and Tissue Biology: A Textbook of Histology. Baltimore, MD: Urban and Schwarzenberg, 1983, pp 353-400.
15. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438, 932, 2005.
16. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964, 1997.
17. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87, 728, 2000.
18. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8, 464, 2007.
19. Risau W. Mechanisms of angiogenesis. Nature 386, 671, 1997.
20. Goodger AM, Rogers PA. Blood vessel growth in the endometrium. Microcirculation 2, 329, 1995.
21. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8, 221, 2007.
22. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154, 1069, 2001.
23. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569, 1994.
24. Gerhardt H, Betsholtz C. How do endothelial cells orientate? EXS 3, 2005.
25. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161, 1163, 2003.
26. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 276, 37491, 2001.
27. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365, 1998.
28. Seandel M, Noack-Kunnmann K, Zhu D, Aimes RT, Quigley JP. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 97, 2323, 2001.
29. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 209, 2005.
30. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7, 575, 2001.
31. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325, 257, 1987.
32. Egginton S, Gerritsen M. Lumen formation: in vivo versus in vitro observations. Microcirculation 10, 45, 2003.
33. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314, 15, 2003.
34. Jain RK. Molecular regulation of vessel maturation. Nat Med 9, 685, 2003.
35. Park C, Ma YD, Choi K. Evidence for the hemangioblast. Exp Hematol 33, 965, 2005.
36. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97, 3422, 2000.
37. Hoenig MR, Campbell GR, Rolfe BE, Campbell JH. Tissue-engineered blood vessels: alternative to autologous grafts? Arterioscler Thromb Vasc Biol 25, 1128, 2005.
38. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107, 1322, 2003.
39. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297, 1058, 2002.
40. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5, 434, 1999.
41. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102, 1340, 2003.
42. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 938, 36, 2001.
43. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, Böhm M, Nickenig G. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107, 3059, 2003.
44. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E, Böhm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109, 220, 2004.
45. Converse JM, Smahel J, Ballantyne DL Jr, Harper AD. Inosculation of vessels of skin graft and host bed: a fortuitous encounter. Br J Plas Surg 28, 274, 1975.
46. Niklason LE. Techview: medical technology. Replacement arteries made to order. Science 286, 1493, 1999.
47. Nerem RM. Tissue engineering a blood vessel substitute. The role of biomechanics. Yonsei Med J 41, 735, 2000.
48. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 288, 551, 1980.
49. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 111, 3621, 1998.
50. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97, 1648, 1983.
51. D'Amore PA. Capillary growth: a two-cell system. Semin Cancer Biol 3, 49, 1992.
52. Black AF, Berthod F, L'Heureux N, Germain L, Auger FA. In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. Faseb J 12, 1331, 1998.
53. Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, Darland DC, Marini R, van Blitterswijk CA, Mulligan RC, D'Amore PA, Langer R. Engineering vascularized skeletal muscle tissue. Nat Biotechnol 23, 879, 2005.
54. Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-Honigmann MR, Lorber MI, Tellides G, Kashgarian M, Bothwell AL, Pober JS. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A 97, 9191, 2000.
55. Zheng L, Dengler TJ, Kluger MS, Madge LA, Schechner JS, Maher SE, Pober JS, Bothwell AL. Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL-mediated lysis provided by caspase-resistant Bcl-2 without alterations in growth or activation responses. J Immunol 164, 4665, 2000.
56. Enis DR, Shepherd BR, Wang Y, Qasim A, Shanahan CM, Weissberg PL, Kashgarian M, Pober JS, Schechner JS. Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. Proc Natl Acad Sci U S A 102, 425, 2005.
57. Dutt K, Sanford G, Harris-Hooker S, Brako L, Kumar R, Sroufe A, Melhado C. Three-dimensional model of angiogenesis: coculture of human retinal cells with bovine aortic endothelial cells in the NASA bioreactor. Tissue Eng 9, 893, 2003.
58. Neumann T, Nicholson BS, Sanders JE. Tissue engineering of perfused microvessels. Microvasc Res 66, 59, 2003.
59. Helm CL, Fleury ME, Zisch AH, Boschetti F, Swartz MA. Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc Natl Acad Sci U S A 102, 15779, 2005.
60. Helm CL, Zisch A, Swartz MA. Engineered blood and lymphatic capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow. Biotechnol Bioeng 96, 167, 2007.
61. Ng CP, Helm CL, Swartz MA. Interstitial flow differentially stimulates blood and lymphatic endothelial cell morphogenesis in vitro. Microvasc Res 68, 258, 2004.
62. Shepherd BR, Enis DR, Wang F, Suarez Y, Pober JS, Schechner JS. Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells. Faseb J 20, 1739, 2006.
63. Campbell GR, Campbell JH. Development of tissue engineered vascular grafts. Curr Pharm Biotechnol 8, 43, 2007.
64. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. Tissue engineering: creation of long-lasting blood vessels. Nature 428, 138, 2004.
65. Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, Arzigian M, Fukumura D, Jain RK, Scadden DT. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 25, 317, 2007.
66. Black MJ, Chait L, O'Brien BM, Sykes PJ, Sharzer LA. How soon may the axial vessels of a surviving free flap be safely ligated: a study in pigs. Br J Plast Surg 31, 295, 1978.
67. Sieminski AL, Gooch KJ. Biomaterial-microvasculature interactions. Biomaterials 21, 2232, 2000.
68. McIntire LV. Vascular assembly in engineered and natural tissues. Ann N Y Acad Sci 961, 246, 2002.
69. Young DM, Greulich KM, Weier HG. Species-specific in situ hybridization with fluorochrome-labeled DNA probes to study vascularization of human skin grafts on athymic mice. J Burn Care Rehabil 17, 305, 1996.
70. Mian R, Morrison WA, Hurley JV, Penington AJ, Romeo R, Tanaka Y, Knight KR. Formation of new tissue from an arteriovenous loop in the absence of added extracellular matrix. Tissue Eng 6, 595, 2000.
71. Lokmic Z, Stillaert F, Morrison WA, Thompson EW, Mitchell GM. An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct. Faseb J 21, 511, 2007.
72. Balamurugan AN, Gu Y, Tabata Y, Miyamoto M, Cui W, Hori H, Satake A, Nagata N, Wang W, Inoue K. Bioartificial pancreas transplantation at prevascularized intermuscular space: effect of angiogenesis induction on islet survival. Pancreas 26, 279, 2003.
73. Elcin AE, Elcin YM. Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA sponge. Tissue Eng 12, 959, 2006.
74. Elcin YM, Dixit V, Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif Organs 25, 558, 2001.
75. Hiraoka Y, Yamashiro H, Yasuda K, Kimura Y, Inamoto T, Tabata Y. In situ regeneration of adipose tissue in rat fat pad by combining a collagen scaffold with gelatin microspheres containing basic fibroblast growth factor. Tissue Eng 12, 1475, 2006.
76. Lee H, Cusick RA, Browne F, Ho Kim T, Ma PX, Utsunomiya H, Langer R, Vacanti JP. Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices. Transplantation 73, 1589, 2002.
77. Miki A, Rivas-Carrillo JD, Navarro-Alvarez N, Soto-Gutierrez A, Chen Y, Tanaka K, Narushima M, Tabata Y, Okitsu T, Noguchi H, Matsumoto S, Tanaka N, Kobayashi N. Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant. Cell Transplant 15, 893, 2006.
78. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A 65, 489, 2003.
79. Peter SJ, Miller MJ, Yasko AW, Yaszemski MJ, Mikos AG. Polymer concepts in tissue engineering. J Biomed Mater Res 43, 422, 1998.
80. Peters MC, Isenberg BC, Rowley JA, Mooney DJ. Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed 9, 1267, 1998.
81. Peters MC, Polverini PJ, Mooney DJ. Engineering vascular networks in porous polymer matrices. J Biomed Mater Res 60, 668, 2002.
82. Tabata Y, Miyao M, Inamoto T, Ishii T, Hirano Y, Yamaoki Y, Ikada Y. De novo formation of adipose tissue by controlled release of basic fibroblast growth factor. Tissue Eng 6, 279, 2000.
83. Lokmic Z, Idrizi R, Messina A, Knight KR, Morrison WA, Mitchell GM. Vascularization of engineered constructs. In: Wnek G, Bowlin G, eds. Encyclopedia of Biomaterials and Biomedical Engineering. New York: Marcel Dekker, 2004, pp 1750-1759.
84. Erol OO, Spira M. New capillary bed formation with a surgically constructed arteriovenous fistula. Surg Forum 30, 530, 1979.
85. Morrison WA, Dvir E, Doi K, Hurley JV, Hickey MJ, O'Brien BM. Prefabrication of thin transferable axial-pattern skin flaps: an experimental study in rabbits. Br J Plast Surg 43, 645, 1990.
86. Cronin KJ, Messina A, Knight KR, Cooper-White JJ, Stevens GW, Penington AJ, Morrison WA. New murine model of spontaneous autologous tissue engineering, combining an arteriovenous pedicle with matrix materials. Plast Reconstr Surg 113, 260, 2004.
87. Cao Y, Mitchell G, Messina A, Price L, Thompson E, Penington A, Morrison W, O'Connor A, Stevens G, Cooper-White J. The influence of architecture on degradation and tissue ingrowth into three-dimensional poly (lactic-co-glycolic acid) scaffolds in vitro and in vivo. Biomaterials 27, 2854, 2006.
88. Cassell OC, Morrison WA, Messina A, Penington AJ, Thompson EW, Stevens GW, Perera JM, Kleinman HK, Hurley JV, Romeo R, Knight KR. The influence of extracellular matrix on the generation of vascularized, engineered, transplantable tissue. Ann N Y Acad Sci 944, 429, 2001.
89. Morritt AN, Bortolotto SK, Dilley RJ, Han X, Kompa AR, McCombe D, Wright CE, Itescu S, Angus JA, Morrison WA. Cardiac tissue engineering in an in vivo vascularized chamber. Circulation 115, 353, 2007.
90. Messina A, Bortolotto SK, Cassell OC, Kelly J, Abberton KM, Morrison WA. Generation of a vascularized organoid using skeletal muscle as the inductive source. Faseb J 19, 1570, 2005.
91. Kelly JL, Findlay MW, Knight KR, Penington A, Thompson EW, Messina A, Morrison WA. Contact with existing adipose tissue is inductive for adipogenesis in matrigel. Tissue Eng 12, 2041, 2006.
92. Polykandriotis E, Tjiawi J, Euler S, Arkudas A, Hess A, Brune K, Greil P, Lametschwandtner A, Horch RE, Kneser U. The venous graft as an effector of early angiogenesis in a fibrin matrix. Microvasc Res 75, 25, 2008.
93. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9, 604, 2003.
94. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118, 3759, 2005.
95. Ley CD, Olsen MW, Lund EL, Kristjansen PE. Angiogenic synergy of bFGF and VEGF is antagonized by Angiopoietin-2 in a modified in vivo Matrigel assay. Microvasc Res 68, 161, 2004.
96. Rophael JA, Craft RO, Palmer JA, Hussey AJ, Thomas GP, Morrison WA, Penington AJ, Mitchell GM. Angiogenic growth factor synergism in a murine tissue-engineering model of angiogenesis and adipogenesis. Am J Pathol 171, 2048, 2007.
97. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 19, 1029, 2001.
98. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13, 18, 1992.
99. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family. identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5, 1806, 1991.
100. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and posttranscriptional regulatory sequences. J Biol Chem 271, 3877, 1996.
101. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 104, 115, 2001.
102. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 3, 158, 1997.
103. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7, 425, 2001.
104. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113, 516, 2004.
105. Lee KY, Peters MC, Mooney DJ. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release 87, 49, 2003.
106. Lu Y, Shansky J, Del Tatto M, Ferland P, Wang X, Vandenburgh H. Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis. Circulation 104, 594, 2001.
107. Felmeden DC, Blann AD, Lip GY. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 24, 586, 2003.
108. Elcin YM, Dixit V, Gitnick G. Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis: in vitro and in vivo studies. Artif Cells Blood Substit Immobil Biotechnol 24, 257, 1996.
109. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105, 732, 2002.
110. Gyongyosi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J, Jorgensen E, Hesse B, Tägil K, Bøtker HE, Ruzyllo W, Teresiñska A, Dudek D, Hubalewska A, Rück A, Nielsen SS, Graf S, Mundigler G, Novak J, Sochor H, Maurer G, Glogar D, Sylven C. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112, I157, 2005.
111. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370, 1996.
112. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800, 1998.
113. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP, Hospers GA. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 17, 683, 2006.
114. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362, 844, 1993.
115. Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 310, 175, 1984.
116. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 85, 1414, 2000.
117. Sprugel KH, McPherson JM, Clowes AW, Ross R. Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers. Am J Pathol 129, 601, 1987.
118. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res 56, 216, 2001.
119. Kawai K, Suzuki S, Tabata Y, Ikada Y, Nishimura Y. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials 21, 489, 2000.
120. Vashi AV, Abberton KM, Thomas GP, Morrison WA, O'Connor AJ, Cooper-White JJ, Thompson EW. Adipose tissue engineering based on the controlled release of fibroblast growth factor-2 in a collagen matrix. Tissue Eng 12, 3035, 2006.
121. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, Quyyumi AA. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36, 1239, 2000.
122. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100, 1865, 1999.
123. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 124, 28, 2002.
124. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). B J Pharmacol 140, 637, 2003.
125. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359, 2053, 2002.
126. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242, 1997.
127. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591, 1998.
128. Hallmann R, Horn N, Selg M, Wendler O, Pausch F, Sorokin LM. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 85, 979, 2005.
129. Dejana E, Lampugnani MG, Giorgi M, Gaboli M, Marchisio PC. Fibrinogen induces endothelial cell adhesion and spreading via the release of endogenous matrix proteins and the recruitment of more than one integrin receptor. Blood 75, 1509, 1990.
130. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96, 3772, 2000.
131. Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood 107, 126, 2006.
132. Freed LE, Vunjak-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK, Langer R. Biodegradable polymer scaffolds for tissue engineering. Biotechnology (N Y) 12, 689, 1994.
133. Ko HC, Milthorpe BK, McFarland CD. Engineering thick tissues - the vascularization problem. Eur Cell Mater 14, 1, 2007.
134. Velema J, Kaplan D. Biopolymer-based biomaterials as scaffolds for tissue engineering. Adv Biochem Eng Biotechnol 102, 187, 2006.
135. Lavik E, Langer R. Tissue engineering. Current state and perspectives. Appl Microbiol Biotechnol 65, 1, 2004.
136. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 86-A, 1541, 2004.
137. Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 81, 439, 2001.
138. Collen A, Koolwijk P, Kroon M, van Hinsbergh VW. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 2, 153, 1998.
139. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VW. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60, 6196, 2000.
140. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater 71, 343, 2004.
141. Schmidt CE, Baier JM. Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials 21, 2215, 2000.
142. Stitzel J, Liu J, Lee SJ, Komura M, Berry J, Soker S, Lim G, Van Dyke M, Czerw R, Yoo JJ, Atala A. Controlled fabrication of a biological vascular substitute. Biomaterials 27, 1088, 2006.
143. Salem AK, Stevens R, Pearson RG, Davies MC, Tendler SJ, Roberts CJ, Williams PM, Shakesheff KM. Interactions of 3T3 fibroblasts and endothelial cells with defined pore features. J Biomed Mater Res 61, 212, 2002.
144. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. III. Effective tissue response times. J Biomed Mater Res 40, 598, 1998.
145. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. J Biomed Mater Res 40, 586, 1998.
146. Chung HJ, Kim HK, Yoon JJ, Park TG. Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm Res 23, 1835, 2006.
147. Yoon JJ, Chung HJ, Lee HJ, Park TG. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res A 79, 934, 2006.
148. Sung HJ, Meredith C, Johnson C, Galis ZS. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 25, 5735, 2004.
149. Kaushiva A, Turzhitsky VM, Backman V, Ameer GA. A biodegradable vascularizing membrane: a feasibility study. Acta Biomaterialia 3, 631, 2007.
150. Anderson JM. Inflammatory response to implants. ASAIO Trans 34, 101, 1988.
151. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 29, 1517, 1995.
152. Padera RF, Colton CK. Time course of membrane microarchitecture-driven neovascularization. Biomaterials 17, 277, 1996.
153. Kaihara S, Borenstein J, Koka R, Lalan S, Ochoa ER, Ravens M, Pien H, Cunningham B, Vacanti JP. Silicon micromachining to tissue engineer branched vascular channels for liver fabrication. Tissue Eng 6, 105, 2000.
154. Peirce SM, Van Gieson EJ, Skalak TC. Multicellular simulation predicts microvascular patterning and in silico tissue assembly. Faseb J 18, 731, 2004.
155. Hou S, Xu Q, Tian W, Cui F, Cai Q, Ma J, Lee IS. The repair of brain lesion by implantation of hyaluronic acid hydrogels modified with laminin. J Neurosci Meth 148, 60, 2005.
156. Chen R, Curran SJ, Curran JM, Hunt JA. The use of poly (1-lactide) and RGD modified microspheres as cell carriers in a flow intermittency bioreactor for tissue engineering cartilage. Biomaterials 27, 4453, 2006.
157. Connelly JT, Garcia AJ, Levenston ME. Inhibition of in vitro chondrogenesis in RGD-modified three-dimensional alginate gels. Biomaterials 28, 1071, 2007.
158. Petrie TA, Capadona JR, Reyes CD, Garcia AJ. Integrin specificity and enhanced cellular activities associated with surfaces presenting a recombinant fibronectin fragment compared to RGD supports. Biomaterials 27, 5459, 2006.
159. Mooney DJ, Hansen LK, Langer R, Vacanti JP, Ingber DE. Extracellular matrix controls tubulin monomer levels in hepatocytes by regulating protein turnover. Mol Biol Cell 5, 1281, 1994.
160. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146, 56, 1995.
161. Lang R, Lustig M, Francois F, Sellinger M, Plesken H. Apoptosis during macrophage-dependent ocular tissue remodelling. Development 120, 3395, 1994.
162. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273, 13313, 1998.
163. Baluk P, Lee CG, Link H, Ator E, Haskell A, Elias JA, McDonald DM. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol 165, 1071, 2004.
164. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86, 24, 2000.
165. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55, 1997.
166. Dejana E. Endothelial cell-cell junctions: happy together. Nature Rev 5, 261, 2004.
167. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 355, 1, 2007.
168. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41, 2000.
169. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843, 1992.
170. Ichioka S, Shibata M, Kosaki K, Sato Y, Harii K, Kamiya A. Effects of shear stress on wound-healing angiogenesis in the rabbit ear chamber. J Surg Res 72, 29, 1997.
171. van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 936, 426, 2001.
172. Alenghat FJ, Ingber DE. Mechanotransduction. All signals point to cytoskeleton, matrix, and integrins. Sci STKE 2002, PE6, 2002.
173. Pries AR, Reglin B, Secomb TW. Remodeling of blood vessels. Responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension 46, 725, 2005.